MedPath

Phase 1 study to evaluate the safety and efficacy of jyuzentaihoto in infantile anal fistula

Phase 1
Conditions
infantile anal fistula
Registration Number
JPRN-UMIN000021336
Lead Sponsor
Kanazawa University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Any of the following: currently receiving a drug therapy, currently having chronic diseases such as heart, lung, kidney, gastrointestinal, and inflammatory diseases, suffering from invasive cancer within five years, suffering from non-invasive cancer within a year, and having taken Kampo medicine within 2 weeks.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
rate of cure after two and four weeks
Secondary Outcome Measures
NameTimeMethod
The influence on gut flora and the safety after the administration of jyuzentaihoto
© Copyright 2025. All Rights Reserved by MedPath